{"Symbol": "ALZN", "AssetType": "Common Stock", "Name": "Alzamend Neuro Inc", "Description": "Alzamend Neuro Inc. is a biotechnology firm dedicated to the development of innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company utilizes a proprietary platform to tackle unmet medical needs, enhancing its drug development processes through advanced technology integration. With a robust intellectual property portfolio and strategic collaborations, Alzamend is well-positioned to capitalize on significant market opportunities in the pharmaceutical sector. As it progresses its therapeutic candidates through clinical trials, the firm remains committed to improving patient quality of life and addressing critical health challenges.", "CIK": "1677077", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "3480 PEACHTREE ROAD NE, ATLANTA, GA, UNITED STATES, 30326", "OfficialSite": "https://www.alzamend.com", "FiscalYearEnd": "April", "LatestQuarter": "2025-10-31", "MarketCapitalization": "6196600", "EBITDA": "-5793921", "PERatio": "None", "PEGRatio": "None", "BookValue": "1.151", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.67", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.727", "ReturnOnEquityTTM": "-1.448", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-2.67", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "28", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "1.417", "EVToRevenue": "-", "EVToEBITDA": "-3.133", "Beta": "-0.236", "52WeekHigh": "10.35", "52WeekLow": "1.58", "50DayMovingAverage": "2.117", "200DayMovingAverage": "2.698", "SharesOutstanding": "3801600", "SharesFloat": "3789700", "PercentInsiders": "2.175", "PercentInstitutions": "5.790", "DividendDate": "None", "ExDividendDate": "None"}